<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED</B><FONT STYLE="font-size: 10pt">
</FONT> <FONT STYLE="font-size: 10pt"> </FONT><B>STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27pt">Date of report (Date
of earliest event reported): <B>May</B> <B>7, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHINA SHENGHUO PHARMACEUTICAL HOLDINGS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact Name of Registrant as Specified
in Its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or Other Jurisdiction</I> <I>of
Incorporation)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-align: center">001-33537</TD>
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-align: center">20-2903562</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(Commission File Number)</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold; text-align: center">No. 2, Jing You Road</TD>
    <TD STYLE="width: 50%">&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">Kunming National Economy &amp;</TD>
    <TD>&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">Technology Developing District</TD>
    <TD>&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">People&rsquo;s Republic of China 650217</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">N/A</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="font-style: italic; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>0086-871-728-2628</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(</I> <I>Registrant&rsquo;s Telephone
Number, Including Area Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Former Name or Former Address, if Changed
Since Last Report)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a Press Release dated April 20, 2012,
China Shenghuo Pharmaceutical Holdings, Inc. (the &ldquo;Company&rdquo;) announced its intention to file a Form 15, which would,
upon such filing, suspend the Company's obligations to file certain reports with the U.S. Securities &amp; Exchange Commission
(the &ldquo;SEC&rdquo;), including reports on Form 10-K, 10-Q, and 8-K. It was anticipated that such Form 15 would be filed on
or about May 10, 2012, upon the effectiveness of the Form 25 - Notification of Removal from Listing and/or Registration under Section
12(b) of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;), filed in connection with the Company's
voluntary delisting of its common stock from trading on NYSE Amex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In discussions between the Company's legal
counsel and the SEC, the SEC has taken the position that the exemption that the Company had sought to rely upon under Section 15(d)
of the Exchange Act to suspend its reporting obligations is unavailable to it at this time. As such, the Company at this time will
not file a Form 15, and it will continue to be a reporting company under Section 15(d) of the Exchange Act until such time as it
is allowed to suspend its reporting obligations, which the Company expects to be no later than the first quarter of 2013. The Company
therefore is preparing its quarterly report on Form 10-Q for the three months ended March 31, 2012, and expects to file it as soon
as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 7, 2012, the Company issued
a press release announcing its intent not to file Form 15 at this time and continue to be a reporting company until such time
as it is allowed to suspend its reporting obligations. A copy of that press release is furnished herewith as Exhibit 99.1 and is
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This current report on Form 8-K may contain
certain &quot;forward-looking statements,&quot; as defined in the United States Private Securities Litigation Reform Act of 1995,
that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and
the actual results and future events could differ materially from management's current expectations. Such factors include, but
are not limited to, uncertainties regarding the eligibility for and timing of the Company&rsquo;s planned deregistration under
the Exchange Act, including any relief that the SEC might grant to the Company pursuant to a &ldquo;no-action&rdquo; letter with
respect to the SEC deregistration requirements should the Company seek such relief; risks of litigation and governmental or other
regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out
of the restatement of the Company's financial statements; the Company's ability to refinance or repay loans received; the Company's
uncertain business condition; risks related to the lower liquidity, trading volume and price resulting from the voluntary delisting
of the Company&rsquo;s stock and the anticipated deregistration under the Exchange Act; risks arising from potential weaknesses
or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi;
the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability
to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability
to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its
cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of
the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the
Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on
the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with
the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.</B> <B>Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">(d)</TD>
    <TD STYLE="width: 94%">Exhibits.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="width: 3%; padding-bottom: 1.5pt">&nbsp;&nbsp;</TD>
    <TD STYLE="width: 87%; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>&nbsp;&nbsp;</TD>
    <TD>Press Release, dated May 7, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 7, 2012</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: white 3pt solid">By:</TD>
    <TD NOWRAP STYLE="border-bottom: black 1.5pt solid">/s/ Feng Lan</TD>
    <TD STYLE="border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Feng Lan</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: Chief Executive Officer and President</P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="width: 3%; padding-bottom: 1.5pt">&nbsp;&nbsp;</TD>
    <TD STYLE="width: 87%; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>&nbsp;&nbsp;</TD>
    <TD>Press Release, dated May 7, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v312135_8-k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 20146}]
{"company-data": {"conformed-name": "China Shenghuo Pharmaceutical Holdings Inc", "cik": "0001335106", "assigned-sic": "2834", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33537", "film-number": "12816670"}, "business-address": {"street1": "NO. 2, JING YOU ROAD", "street2": "KUNMING NATIONAL ECONOMY &", "city": "TECHNOLOGY DEVELOPING DISTRICT", "state": "F4", "zip": "00000", "phone": "0086-871-7282628"}, "mail-address": {"street1": "NO. 2, JING YOU ROAD", "street2": "KUNMING NATIONAL ECONOMY &", "city": "TECHNOLOGY DEVELOPING DISTRICT", "state": "F4", "zip": "00000"}, "former-company": {"former-conformed-name": "SRKP 8 INC", "date-changed": "20050803"}}
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date
of earliest event reported):
May
7, 2012
CHINA SHENGHUO PHARMACEUTICAL HOLDINGS,
INC.
(Exact Name of Registrant as Specified
in Its Charter)
Delaware
(State or Other Jurisdiction
of
Incorporation)
001-33537
20-2903562
(Commission File Number)
(IRS Employer Identification No.)
No. 2, Jing You Road
Kunming National Economy &
Technology Developing District
People's Republic of China 650217
N/A
(Address of Principal Executive Offices)
(Zip Code)
0086-871-728-2628
(
Registrant's Telephone
Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
In a Press Release dated April 20, 2012,
China Shenghuo Pharmaceutical Holdings, Inc. (the "Company") announced its intention to file a Form 15, which would,
upon such filing, suspend the Company's obligations to file certain reports with the U.S. Securities & Exchange Commission
(the "SEC"), including reports on Form 10-K, 10-Q, and 8-K. It was anticipated that such Form 15 would be filed on
or about May 10, 2012, upon the effectiveness of the Form 25 - Notification of Removal from Listing and/or Registration under Section
12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), filed in connection with the Company's
voluntary delisting of its common stock from trading on NYSE Amex.
In discussions between the Company's legal
counsel and the SEC, the SEC has taken the position that the exemption that the Company had sought to rely upon under Section 15(d)
of the Exchange Act to suspend its reporting obligations is unavailable to it at this time. As such, the Company at this time will
not file a Form 15, and it will continue to be a reporting company under Section 15(d) of the Exchange Act until such time as it
is allowed to suspend its reporting obligations, which the Company expects to be no later than the first quarter of 2013. The Company
therefore is preparing its quarterly report on Form 10-Q for the three months ended March 31, 2012, and expects to file it as soon
as practicable.
On May 7, 2012, the Company issued
a press release announcing its intent not to file Form 15 at this time and continue to be a reporting company until such time
as it is allowed to suspend its reporting obligations. A copy of that press release is furnished herewith as Exhibit 99.1 and is
incorporated herein by reference.
Safe Harbor Statement
This current report on Form 8-K may contain
certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995,
that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and
the actual results and future events could differ materially from management's current expectations. Such factors include, but
are not limited to, uncertainties regarding the eligibility for and timing of the Company's planned deregistration under
the Exchange Act, including any relief that the SEC might grant to the Company pursuant to a "no-action" letter with
respect to the SEC deregistration requirements should the Company seek such relief; risks of litigation and governmental or other
regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out
of the restatement of the Company's financial statements; the Company's ability to refinance or repay loans received; the Company's
uncertain business condition; risks related to the lower liquidity, trading volume and price resulting from the voluntary delisting
of the Company's stock and the anticipated deregistration under the Exchange Act; risks arising from potential weaknesses
or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi;
the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability
to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability
to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its
cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of
the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the
Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on
the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with
the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number
Description
99.1
Press Release, dated May 7, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC.
Date: May 7, 2012
By:
/s/ Feng Lan
Name: Feng Lan
Title: Chief Executive Officer and President
EXHIBIT INDEX
Exhibit
Number
Description
99.1
Press Release, dated May 7, 2012.